Xponance Inc. Sells 895 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Xponance Inc. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,089 shares of the biopharmaceutical company’s stock after selling 895 shares during the period. Xponance Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,697,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ALNY. Quent Capital LLC grew its holdings in Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. KB Financial Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $35,000. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $38,000. First Capital Advisors Group LLC. purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $80,000. Finally, 1832 Asset Management L.P. bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $88,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.5 %

ALNY opened at $144.41 on Monday. The firm has a market cap of $18.19 billion, a price-to-earnings ratio of -40.56 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $143.50 and a 12 month high of $218.88. The stock has a fifty day moving average price of $151.56 and a 200-day moving average price of $166.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.68) earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ALNY. HC Wainwright reiterated a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Needham & Company LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. Wolfe Research initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Finally, The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $230.00 to $173.00 in a research note on Friday, February 16th. Nine analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.